Irish-listed pharma company Hvivo hails record year with 30% revenue growth

Pharmaceutical services firm Hvivo, formerly Open Orphan, will pay a dividend to shareholders after a “record financial and operational performance” last year.

The Dublin and London-listed organisation is set to pay a one-off special dividend of £3m (€3.4m) in June following “strong cash generation” in 2022.

Revenues rose by 30pc across the year to £50.7m, while the group’s cash position stood at £28.4m at the end of 2022, up from £15.7m in 2021.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO fast-tracks drug trials and draws big pharma in

    In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight pharmaceutical partners along the way. hVIVO